Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
about
Algorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacyCarlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study.H-gemcitabine: a new gemcitabine prodrug for treating cancerDifferential response to hypomethylating agents based on sex: a report on behalf of the MDS Clinical Research Consortium (MDS CRC).Gemcitabine diphosphate choline is a major metabolite linked to the Kennedy pathway in pancreatic cancer models in vivo.Plasma pharmacokinetics and oral bioavailability of the 3,4,5,6-tetrahydrouridine (THU) prodrug, triacetyl-THU (taTHU), in mice.Tetrahydrouridine inhibits cell proliferation through cell cycle regulation regardless of cytidine deaminase expression levelsA miRNA signature of chemoresistant mesenchymal phenotype identifies novel molecular targets associated with advanced pancreatic cancer.Effects of tetrahydrouridine on pharmacokinetics and pharmacodynamics of oral decitabineCell-Based High-Throughput Screening Assay Identifies 2',2'-Difluoro-2'-deoxycytidine Gemcitabine as a Potential Antipoliovirus Agent.p53-Independent, normal stem cell sparing epigenetic differentiation therapy for myeloid and other malignanciesnab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.High cytidine deaminase expression in the liver provides sanctuary for cancer cells from decitabine treatment effects.CTGF antagonism with mAb FG-3019 enhances chemotherapy response without increasing drug delivery in murine ductal pancreas cancerDevelopment of gene therapy in association with clinically used cytotoxic deoxynucleoside analogues.Deoxyuridine analog nucleotides in deoxycytidine analog treatment: secondary active metabolites?Subchronic oral toxicity study of decitabine in combination with tetrahydrouridine in CD-1 mice.In vitro and in vivo studies of pharmacokinetics and antitumor efficacy of D07001-F4, an oral gemcitabine formulation.Characterization of permeability, stability and anti-HIV-1 activity of decitabine and gemcitabine divalerate prodrugs.Oral tetrahydrouridine and decitabine for non-cytotoxic epigenetic gene regulation in sickle cell disease: A randomized phase 1 study.Phase I study of veliparib in combination with gemcitabine.Fluorinated nucleosides as an important class of anticancer and antiviral agents.LC-MS/MS assay for the quantitation of the ribonucleotide reductase inhibitor triapine in human plasma.Fetal Hemoglobin Induction by Epigenetic Drugs
P2860
Q28484288-CC4623B8-FFCD-4CC5-B625-F64C345DCC4DQ33415914-1A270011-7EB0-4481-9194-D69FAD6D8FC2Q33572635-C6EED3F2-A5A0-4FFD-AD65-4FAEB217DCDCQ33573681-9DF7A12C-B8D0-4D6A-89AB-59E06321F26EQ33918107-4383D0BB-04C6-4D6A-B9A8-357AFCF7121BQ34195332-03809C51-DD43-4EB0-9453-2ED3AD673A6CQ34278045-A672F489-61DC-49DE-AF44-EB28CD6D66CCQ35237480-A60240C4-33D1-4013-A0E0-C4FD9C563D7FQ35750354-BF19A753-9BDA-412B-B1EF-7BC78F0D856CQ36161679-20ED45A1-796A-497E-B04E-CF7533DDC1E8Q36848202-8F99D2F8-A370-466F-A9BC-415B784CF53FQ36901035-A7E6DEF9-9102-4E7F-BE31-D8278A0C9DE3Q37031262-EE1EC9E6-A91B-4B2C-BF13-5A0446C4EB19Q37049583-A5272178-69DA-4DDD-BFA2-2A437868DA77Q37431500-694A1206-F195-4B1A-AC89-3E6C97177B32Q37701947-678BE639-E8FF-43A9-BDA3-DF86093FE878Q37725734-CC851955-5126-4119-B1E8-7F8284DD5978Q39246575-5F798E05-4867-4329-AC9D-69149836BA42Q41480926-4920B158-77A5-48D4-B0DB-E9DB9B47B1CCQ41576877-52566F7C-FC31-4F5E-9448-486354545875Q47100777-456D4D87-B4FE-4A99-8529-E381782A85E5Q47637142-FFD85279-95ED-4D7C-9907-C2E416C7BFC2Q47841713-1827FBFF-4F6C-468E-A85D-6689CABE12DCQ57753972-ACBE4391-3F8A-44BE-9AAB-1262474DF1C4
P2860
Modulation of gemcitabine (2',2'-difluoro-2'-deoxycytidine) pharmacokinetics, metabolism, and bioavailability in mice by 3,4,5,6-tetrahydrouridine.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年学术文章
@wuu
2008年学术文章
@zh
2008年学术文章
@zh-cn
2008年学术文章
@zh-hans
2008年学术文章
@zh-my
2008年学术文章
@zh-sg
2008年學術文章
@yue
2008年學術文章
@zh-hant
name
Modulation of gemcitabine (2', ...... by 3,4,5,6-tetrahydrouridine.
@en
Modulation of gemcitabine (2', ...... by 3,4,5,6-tetrahydrouridine.
@nl
type
label
Modulation of gemcitabine (2', ...... by 3,4,5,6-tetrahydrouridine.
@en
Modulation of gemcitabine (2', ...... by 3,4,5,6-tetrahydrouridine.
@nl
prefLabel
Modulation of gemcitabine (2', ...... by 3,4,5,6-tetrahydrouridine.
@en
Modulation of gemcitabine (2', ...... by 3,4,5,6-tetrahydrouridine.
@nl
P2093
P1476
Modulation of gemcitabine (2', ...... e by 3,4,5,6-tetrahydrouridine
@en
P2093
Erin Joseph
Joseph M Covey
Julie L Eiseman
Merrill J Egorin
Robert A Parise
P304
P356
10.1158/1078-0432.CCR-07-4885
P407
P50
P577
2008-06-01T00:00:00Z